In patients with NSCLC, single agent anti-PD-1 therapy with pembrolizumab leads to a survival benefit for patients with advanced NSCLC, with a high immunohistochemical expression of PD-L1 (≥50%) on tumor cells. This evidence concerns the gene CD274 and neoplasm.